Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Effect of monthly minodronate after switching from raloxifene hydrochloride for the treatment of postmenopausal osteoporosis in women with loss of ovarian function due to gynaecological malignancies

Trial Profile

Effect of monthly minodronate after switching from raloxifene hydrochloride for the treatment of postmenopausal osteoporosis in women with loss of ovarian function due to gynaecological malignancies

Completed
Phase of Trial: Phase IV

Latest Information Update: 12 Mar 2018

At a glance

  • Drugs Minodronic acid (Primary)
  • Indications Postmenopausal osteoporosis
  • Focus Pharmacodynamics; Therapeutic Use
  • Most Recent Events

    • 08 Mar 2018 Status changed from recruiting to completed.
    • 03 Jul 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top